ClinicalTrials.gov
public full text
Public Domain
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls. Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Correction: Impact of immune function and white matter integrity on cognitive function in patients with bipolar disorder.#653258
- Polygenic scores in psychiatric research and clinical practice.#351354
- Reward-Related Brain Function as an Endophenotype in the Mood-Psychosis Spectrum#120102
- Reward-Related Brain Function as an Endophenotype in the Mood-Psychosis Spectrum.#15173
- The Brain Endocannabinoid System is Differentially Regulated in Male and Female Patients with First-Episode Psychosis.#157881
Record · ID 1074821
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive